📰 3 sources covering this story

STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more

First covered 2 days ago · latest take 50 mins ago. Compare how each outlet is covering it — and rate the sources you trust.

STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
STAT News
STAT News50 mins ago
STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
An FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma that the agency has rejected twice
CNBC
CNBC2 days ago
Why shareholders are suing Novo Nordisk over next-generation weight-loss drug
Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.
The Oregonian
The Oregonian🏁 first to report2 days ago
Dear Doctor: Should I take weight loss drug with Type 1 diabetes and retinopathy?
A 73-year-old woman with Type 1 diabetes and heart disease considers Mounjaro for weight loss, but risks and close monitoring are advised.
Top rated outlets
Outlets are ranked once they have 3+ community ratings — be one of the first to rate.
🏆 Most trusted sources 2026 →
Scores come entirely from reader ratings — rate the sources you read to shape them. How it works →